Skip to content

Seeger Weiss Reports Enrollment of 93% of Eligible Plaintiffs in VIOXX Settlement

Seeger Weiss LLP, announced today that 93 percent of eligible individuals have enrolled in the nationwide VIOXX settlement program first announced last November. Under the program, Merck has set aside $4.85 billion to compensate those claimants who suffered a heart attack, ischemic stroke, or sudden cardiac death while taking the drug. Seeger Weiss founding partner, […]

March 3, 2008

Seeger Weiss LLP, announced today that 93 percent of eligible individuals have enrolled in the nationwide VIOXX settlement program first announced last November. Under the program, Merck has set aside $4.85 billion to compensate those claimants who suffered a heart attack, ischemic stroke, or sudden cardiac death while taking the drug.

Seeger Weiss founding partner, Chris Seeger, who was one of the chief negotiators of the settlement, has over the last several months joined other attorneys from Seeger Weiss and the Plaintiffs Negotiating Committee in meeting with lawyers from around the country to guide them through the enrollment process. Given his intimate knowledge of the proceedings, Mr. Seeger is not surprised by the settlement program’s success, stating: ‘While the size and scope of the program is one of the largest and most complex of any pharmaceutical litigation in history, the high rate of enrollment is unprecedented and represents a decisive endorsement of its fairness.’

Mr. Seeger and his firm have been one of the nation’s leaders in the Vioxx litigation since 2001, serving as lead counsel in two trials, resulting in a $47.5 million verdict for the plaintiff in that case, and Co-Lead Counsel for the Plaintiffs Steering Committee in the federal litigation before the Honorable E. Eldon Fallon. His partner, David Buchanan, serves as Co-Liaison Counsel in the New Jersey Vioxx Litigation.

Under the program, those claimants enrolling in the program by February 29, 2008, may qualify to receive an early interim payment of their settlement proceeds. Mr. Seeger and his co-counsel will continue to work with attorneys and the program administrators to facilitate enrollment.

Related News

December 1, 2022
Seeger Weiss now accepting applicants for 2023 Diversity Fellowship

Seeger Weiss LLP announced today that the application period for the firm’s 2023 Diversity Fellowship is now open. Seeger Weiss is committed to providing an inclusive, equitable workplace where team members from all backgrounds can thrive and grow. We believe that diversity makes workplaces, institutions, and our world stronger, smarter, more resilient, and more just. […]

Read More
November 11, 2022
Chris Seeger appointed co-lead counsel in In Re: Social Media Adolescent Addiction/Personal Injury Products Liability Litigation

Seeger Weiss is proud to announce founder Chris Seeger has been appointed to serve as co-lead counsel in the In Re: Social Media Adolescent Addiction/Personal Injury Products Liability Litigation by the honorable Judge Yvonne Gonzalez Rogers. Seeger was one of three lawyers selected to lead the multidistrict litigation pending in the Northern District of California, […]

Read More
November 4, 2022
Seeger Weiss founding partner Chris Seeger helps negotiate $10 billion agreements with Walgreens and CVS in National Prescription Opiate Litigation

Seeger Weiss founding partner Chris Seeger along with partner Jennifer Scullion helped lead the National Prescription Opiate Litigation team in negotiations with Walgreens and CVS that culminated in over $10 billion in settlement agreements to help communities across the country ravaged by the opioid epidemic. In addition to Seeger and Scullion, negotiations were led by […]

Read More